본문 바로가기
KERD
논문KCI 등재

소포림프종의 진단 및 치료의 최신 동향

Recent Updates on Diagnosis and Treatment of Follicular Lymphoma

양덕환|송가영
대한내과학회 (The Korean Association Of Internal Medicine)|2023.10|대한내과학회지 (The Korean Journal of Medicine)|제98권 제5호|pp. 231-240|DOI https://doi.org/10.3904/kjm.2023.98.5.231

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

PrognosisImmunotherapy예후Lymphomafollicular소포림프종면역 치료
주제분류내과학

초록

Follicular lymphoma (FL) is the third most common subtype of non-Hodgkin lymphoma in Korea. Patients with FL generally present with asymptomatic lymphadenopathy, which may wax and wane for years and have indolent disease course. Most patients with FL have advanced-stage disease at diagnosis and less than 20% of patients with FL have stage I/II disease. Radiation therapy is generally accepted with the treatment of choice for limited-stage FL and results in 60-80% of 10-year overall survival rates. Patients with advanced- stage FL do not require an immediate treatment unless they have symptomatic disease, compromised end organ function, B symptoms, or cytopenia. The initial treatment of advanced-stage FL recommends rituximab-containing immunochemotherapy followed by 2 years of maintenance with rituximab, or bendamustine plus rituximab is a preferred choice because of superior progression- free survival with less toxicity than other rituximab-containing immunochemotherapy. For patients with relapsed or refractory FL, there are many options ranging from anti-CD20 monoclonal antibody alone to a combination with lenalidomide and chemotherapy or autologous stem cell transplantation. In addition, the novel approaches for relapsed or refractory FL have been applied with phosphoinositide 3-kinase inhibitor, Bruton’s tyrosine kinase inhibitor, enhancer of zeste homolog 2 inhibitor, anti-CD19 chimeric antigen receptor T-cell therapy and bispecific antibodies.

Abstract

Follicular lymphoma (FL) is the third most common subtype of non-Hodgkin lymphoma in Korea. Patients with FL generally present with asymptomatic lymphadenopathy, which may wax and wane for years and have indolent disease course. Most patients with FL have advanced-stage disease at diagnosis and less than 20% of patients with FL have stage I/II disease. Radiation therapy is generally accepted with the treatment of choice for limited-stage FL and results in 60-80% of 10-year overall survival rates. Patients with advanced- stage FL do not require an immediate treatment unless they have symptomatic disease, compromised end organ function, B symptoms, or cytopenia. The initial treatment of advanced-stage FL recommends rituximab-containing immunochemotherapy followed by 2 years of maintenance with rituximab, or bendamustine plus rituximab is a preferred choice because of superior progression- free survival with less toxicity than other rituximab-containing immunochemotherapy. For patients with relapsed or refractory FL, there are many options ranging from anti-CD20 monoclonal antibody alone to a combination with lenalidomide and chemotherapy or autologous stem cell transplantation. In addition, the novel approaches for relapsed or refractory FL have been applied with phosphoinositide 3-kinase inhibitor, Bruton’s tyrosine kinase inhibitor, enhancer of zeste homolog 2 inhibitor, anti-CD19 chimeric antigen receptor T-cell therapy and bispecific antibodies.

참고문헌 (69)

  1. Freedman A, "Follicular lymphoma : 2018 update on diagnosis and management", Am J Hematol, 93, pp.296~305 (2018)
  2. Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
  3. 김미정, "Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution", Journal of Pathology and Translational Medicine, 55(5), pp.330~337 (2021), 대한병리학회[DOI]
  4. Won-Ju Park, "Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999‒2018", Blood Research, 56(4), pp.301~314 (2021), 대한혈액학회[DOI]
  5. Schmitt C, "The bcl-2", IgH rearrangement in a population of 204 healthy individuals : occurrence, age and gender distribution, breakpoints, and detection method validity, 2006, pp.30, 745~750
  6. Summers KE, "Frequency of the Bcl-2", IgH rearrangement in normal individuals : implications for the monitoring of disease in patients with follicular lymphoma, 2001, pp.19, 420~424
  7. Louissaint A Jr, "Pediatric-type nodal follicular lymphoma : a biologically distinct lymphoma with frequent MAPK pathway mutations", Blood, 128, pp.1093~1100 (2016)
  8. Kamijo K, "Clinical features and outcomes of duodenal-type follicular lymphoma : a single-center retrospective study", EJHaem, 3, pp.379~384 (2022)
  9. Hristov AC, "Cutaneous B-cell lymphomas : 2021 update on diagnosis, risk-stratification, and management", Am J Hematol, 95, pp.1209~1213 (2020)
  10. Freedman AS, "Biology and management of histologic transformation of indolent lymphoma", Hematology Am Soc Hematol Educ Program, 2005, pp.314~320 (2005)
  11. Montoto S, "Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma", J Clin Oncol, 25, pp.2426~2433 (2007)
  12. Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
  13. Federico M, "Follicular lymphoma international prognostic index 2 : a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project", J Clin Oncol, 27, pp.4555~4562 (2009)
  14. Solal-Céligny P, "Follicular lymphoma international prognostic index", Blood, 104, pp.1258~1265 (2004)
  15. Bachy E, "A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy", Blood, 132, pp.49~58 (2018)
  16. Brice P, "Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa : a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte", J Clin Oncol, 15, pp.1110~1117 (1997)
  17. Casulo C, "Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the national lymphocare study", J Clin Oncol, 33, pp.2516~2522 (2015)
  18. fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy : a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS, "J Clin Oncol", 2012, 4317~4322
  19. Luminari S, "The prognostic role of post-induction FDG-PET in patients with follicular lymphoma : a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi(FIL)", Ann Oncol, 25, pp.442~447 (2014)
  20. Galimberti S, "Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma : the FIL FOLL05 trial", Clin Cancer Res, 20, pp.6398~6405 (2014)
  21. Pastore A, "Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry", Lancet Oncol, 16, pp.1111~1122 (2015)
  22. Hübel K, "Controversies in the treatment of follicular lymphoma", Hemasphere, 4, pp.e317~ (2020)
  23. Guadagnolo BA, "Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy", Int J Radiat Oncol Biol Phys, 64, pp.928~934 (2006)
  24. Pugh TJ, "Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation : a surveillance, epidemiology, and end results database analysis", Cancer, 116, pp.3843~3851 (2010)
  25. MacManus M, "Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma : TROG 99. 03", J Clin Oncol, 36, pp.2918~2925 (2018)
  26. Friedberg JW, "Effectiveness of first-line management strategies for stage I follicular lymphoma : analysis of the national lymphocare study", J Clin Oncol, 30, pp.3368~3375 (2012)
  27. Ardeshna KM, "Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma : a randomised controlled trial", Lancet, 362, pp.516~522 (2003)
  28. Herold M, "Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma : an East German Study Group hematology and oncology study", J Clin Oncol, 25, pp.1986~1992 (2007)
  29. Hiddemann W, "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-grade Lymphoma Study Group", Blood, 106, pp.3725~3732 (2005)
  30. Marcus R, "CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma", Blood, 105, pp.1417~1423 (2005)
  31. Marcus R, "Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma", J Clin Oncol, 26, pp.4579~4586 (2008)
  32. Salles G, "Rituximab combined with chemotherapy and interferon in follicular lymphoma patients : results of the GELA-GOELAMS FL2000study", Blood, 112, pp.4824~4831 (2008)
  33. Rummel MJ, "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 noninferiority trial", Lancet, 381, pp.1203~1210 (2013)
  34. Hiddemann W, "Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study : influence of chemotherapy on efficacy and safety", J Clin Oncol, 36, pp.2395~2404 (2018)
  35. Martin P, "A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma(NHL) : CALGB 50803(Alliance)", Ann Oncol, 28, pp.2806~2812 (2017)
  36. Marcus R, "Obinutuzumab for the first-line treatment of follicular lymphoma", N Engl J Med, 377, pp.1331~1344 (2017)
  37. Bachy E, "Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy : a LYSA study", Blood, 139, pp.2338~2346 (2022)
  38. Hoster, E, "Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomised trial of GLSG and OSHO", Hematological Oncology, 35(Suppl 2), pp.32~ (2017)
  39. Rummel MJ, "Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)", Blood, 130(Suppl 1), pp.483~ (2017)
  40. Salles G, "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIMA) : a phase 3, randomised controlled trial", Lancet, 377, pp.42~51 (2011)
  41. Morschhauser F, "90Yttriumibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma : updated results after a median follow-up of 7. 3 years from the international, randomized, Phase III first-lineIndolent trial", J Clin Oncol, 31, pp.1977~1983 (2013)
  42. Lopez-Guillermo A, "A randomized phase II study comparing consolidation with a single dose of 90y ibritumomab tiuxetan(Zevalin®)(Z)vs. maintenance with rituximab(R)for two years in patients with newly diagnosed follicular lymphoma(FL)responding to R-CHOP. Preliminary results at 36 months from randomization", Blood, 122, pp.369~ (2013)
  43. Schaaf M, "High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults", Cochrane Database Syst Rev, 1, pp.CD007678~ (2012)
  44. Dreyling M, "Newly diagnosed and relapsed follicular lymphoma : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 32, pp.298~308 (2021)
  45. Cheson BD, "Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study", J Clin Oncol, 36, pp.2259~2266 (2018)
  46. Leonard JP, "AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma", J Clin Oncol, 37, pp.1188~1199 (2019)
  47. Morschhauser F, "Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma(GALEN) : a multicentre, single-arm, phase 2 study", Lancet Haematol, 6, pp.e429~e437 (2019)
  48. Vidal L, "Rituximab maintenance for the treatment of patients with follicular lymphoma : an updated systematic review and meta-analysis of randomized trials", J Natl Cancer Inst, 103, pp.1799~1806 (2011)
  49. Schouten HC, "High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma : results from the randomized European CUP trial", J Clin Oncol, 21, pp.3918~3927 (2003)
  50. Jurinovic V, "Autologous stem cell transplantation for patients with early progression of follicular lymphoma : a follow-up study of 2 randomized trials from the German low grade lymphoma study group", Biol Blood Marrow Transplant, 24, pp.1172~1179 (2018)
  51. Casulo C, "Autologous transplantation in follicular lymphoma with early therapy failure : a national lymphocare study and center for international blood and marrow transplant research analysis", Biol Blood Marrow Transplant, 24, pp.1163~1171 (2018)
  52. Sureda A, "Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma : a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR", Cancer, 124, pp.1733~1742 (2018)
  53. Gopal AK, "PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma", N Engl J Med, 370, pp.1008~1018 (2014)
  54. Flinn IW, "DYNAMO : a phase II study of duvelisib(IPI-145)in patients with refractory indolent non-Hodgkin lymphoma", J Clin Oncol, 37, pp.912~922 (2019)
  55. Fowler NH, "Umbralisib, a dual PI3Kδ", CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma, 2021, pp.39, 1609~1618
  56. Dreyling M, "Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma : 2-year follow-up of the CHRONOS-1 study", Am J Hematol, 95, pp.362~371 (2020)
  57. Matasar MJ, "Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma(CHRONOS-3) : a double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Oncol, 22, pp.678~689 (2021)
  58. Jacobsen E, "Follicular lymphoma : 2023 update on diagnosis and management", Am J Hematol, 97, pp.1638~1651 (2022)
  59. Gopal AK, "Ibrutinib as treatment for patients with relapsed", refractory follicular lymphoma : results from the open-label, multicenter, phase II DAWN study, 2018, pp.36, 2405~2412
  60. Morschhauser F, "Tazemetostat for patients with relapsed or refractory follicular lymphoma : an open-label, single-arm, multicentre, phase 2 trial", Lancet Oncol, 21, pp.1433~1442 (2020)
  61. Morschhauser F, "Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma : final results from a phase 2 randomised study(ROMULUS)", Lancet Haematol, 6, pp.e254~e265 (2019)
  62. Diefenbach C, "Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma : a cohort of a multicentre, single-arm, phase 1b", 2 study, 2021, pp.8, e891~e901
  63. Jacobson CA, "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma(ZUMA-5) : a single-arm, multicentre, phase 2trial", Lancet Oncol, 23, pp.91~103 (2022)
  64. Fowler NH, "Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial", Nat Med, 28, pp.325~332 (2022)
  65. Budde LE, "Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma : a single-arm, multicentre, phase 2 study", Lancet Oncol, 23, pp.1055~1065 (2022)
  66. Hutchings M, "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1", 2 study, 2021, pp.398, 1157~1169
  67. Hutchings M, "Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial", J Clin Oncol, 39, pp.1959~1970 (2021)
  68. Zinzani PL, "ROSEWOOD : a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma", J Clin Oncol (2023)[DOI]
  69. Bannerji R, "Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies(ELM-1) : results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial", Lancet Haematol, 9, pp.e327~e339 (2022)

관련 논문AI추천

Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advancesRobert Kridel대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제3호Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution고현정, 김미정, 박찬식, 서철원, 윤덕현, 조형우, 허주령, 황희상대한병리학회 · Journal of Pathology and Translational Medicine2021 · 제55권 제5호Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy고영혜, 김석진, 김원석, 류성윤, 맹치훈, 안성우, 지준호, 한성준대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제3호만성 림프구성 백혈병에 대한 최신 지견손상균, 조희정대한내과학회 · 대한내과학회지2021 · 제96권 제3호Chronic lymphocytic leukemia: a clinical review including Korean cohorts전영우, 조석구대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제3호Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)최정혜, Gyeong-Won Lee, Hee Jeong Lee, Hyunkyung Park, Jae Joon Han, Jung Sun Kim, Myoung Joo Kang, Seung-Hyun Nam, Sung Ae Koh, Tae Min Kim, Young Jin Yuh대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제5호

이 간행물의 다른 논문 (7건)

웨어러블 디바이스를 이용한 부정맥 진단의 현황과 과제차명진pp. 205-207사람면역결핍바이러스 감염과 장내세균총: 면역 활성화와 대사 질환과 연관된 마이크로바이옴 연구 고찰주은정pp. 208-211급성호흡곤란증후군의 최신 진료 지침김태완, 김원영pp. 212-2222023년 개정된 지침서에 근거한 중등도 이상의 궤양성 대장염 치료의 최신 지견나수영pp. 223-2302달 동안 지속되는 복통과 설사로 내원한 43세 남자한송희, 윤별아, 남영희pp. 241-248
원문 보기